CN1216470A - 脱氢表雄酮组合治疗方法 - Google Patents

脱氢表雄酮组合治疗方法 Download PDF

Info

Publication number
CN1216470A
CN1216470A CN97193912A CN97193912A CN1216470A CN 1216470 A CN1216470 A CN 1216470A CN 97193912 A CN97193912 A CN 97193912A CN 97193912 A CN97193912 A CN 97193912A CN 1216470 A CN1216470 A CN 1216470A
Authority
CN
China
Prior art keywords
interleukin
patient
group
administration
chemical compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97193912A
Other languages
English (en)
Chinese (zh)
Inventor
帕特里克·T·普伦德加斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1216470A publication Critical patent/CN1216470A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN97193912A 1996-04-17 1997-04-17 脱氢表雄酮组合治疗方法 Pending CN1216470A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1569596P 1996-04-17 1996-04-17
US60/015,695 1996-04-17

Publications (1)

Publication Number Publication Date
CN1216470A true CN1216470A (zh) 1999-05-12

Family

ID=21773003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97193912A Pending CN1216470A (zh) 1996-04-17 1997-04-17 脱氢表雄酮组合治疗方法

Country Status (9)

Country Link
EP (1) EP0901375A1 (xx)
JP (1) JP2000508654A (xx)
KR (1) KR20000005539A (xx)
CN (1) CN1216470A (xx)
AU (1) AU734807B2 (xx)
CA (1) CA2251733A1 (xx)
IL (1) IL126623A0 (xx)
NO (1) NO984851L (xx)
WO (1) WO1997038695A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9915623A (pt) * 1998-11-24 2001-08-14 Hollis Eden Pharmaceuticals Uso de compostos de 17-cetoesteróides e derivados, metabolitos e precursores dos mesmos no tratamento de malária e no tratamento de tripanossomìase africana e americana
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU775614B2 (en) * 1998-11-24 2004-08-05 Harbor Biosciences, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
AU1923500A (en) * 1998-11-27 2000-06-19 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis
WO2014166501A2 (en) * 2013-04-10 2014-10-16 Skau Aps Use of immune suppressive peptides as adjuvants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
IL106725A (en) * 1992-08-20 2000-12-06 Schering Plough Corp Pharmaceutical composition for treating inflammatory bowel disease comprising IL-10
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
IL126623A0 (en) 1999-08-17
JP2000508654A (ja) 2000-07-11
CA2251733A1 (en) 1997-10-23
AU2574197A (en) 1997-11-07
EP0901375A1 (en) 1999-03-17
NO984851L (no) 1998-12-17
AU734807B2 (en) 2001-06-21
KR20000005539A (ko) 2000-01-25
NO984851D0 (no) 1998-10-16
WO1997038695A1 (en) 1997-10-23

Similar Documents

Publication Publication Date Title
TW593336B (en) Low-toxicity human interferon-alpha analog
Donohue et al. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Lim et al. Photopheresis for the treatment of cutaneous T-cell lymphoma
JPH10509955A (ja) 二次性免疫不全症の治療法
CN1031132C (zh) 碳环腺苷类似物的制备方法
JPH072660A (ja) 免疫強化剤及び生理学的に許容され得るその塩
JP2002514193A (ja) 同種幹細胞移植のためのコンディショニング
JP2547162B2 (ja) 哺乳動物における異系移植片拒否反応を抑制するための方法と組成物
CN1238782A (zh) 初乳肽及其用途
US20080019972A1 (en) Method for Amplifying Therapeutic Vaccine Activity
CN1216470A (zh) 脱氢表雄酮组合治疗方法
EP0303687B1 (en) Compositions for enhancing adcc therapy
CN1281368A (zh) 口粘膜细胞因子组合物及其应用
HU223903B1 (hu) Lizozim dimerek új alkalmazása
JPH02111727A (ja) 免疫反応が減少したときの免疫系のためのインターロイキン―２の使用
WO1998047516A1 (en) Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
NO173144B (no) Fremgangsmaate til fremstilling av interferongamma
KR100797050B1 (ko) 아토피성 피부염에 치료효과를 갖는 ｃｄ8 ｔ 세포
EP0265238A2 (en) Composition for treating rheumatoid arthritis
JP2022522914A (ja) 医学的使用
KR20160134989A (ko) 인간 인터류킨-2 단백질을 포함하는 약학조성물
CN110804642B (zh) Gpr174免疫学功能及其用途
TWI690327B (zh) 西瑞香素於預防組織或器官移植排斥或是移植物抗宿主疾病之用途
CN1225016A (zh) 一种抗病毒和抗肿瘤药－白细胞介素－8
CN111214495B (zh) 注射用母牛分枝杆菌在制备用于防治呼吸系rsv感染的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1020005

Country of ref document: HK